Mylan and Momenta to work on 6 biosimilars; Mylan CFO Sheehan to retire; Ex-Turing CEO Shkreli tapped brokerage account to make $5M bail payment;

@FiercePharma: China Animal Healthcare creates embarrassment for stakeholder Lilly. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI: 18 months after the FDA slapped Cadila with a Form 483, it sends a warning letter. More | Follow @EricPFierce

@CarlyHFierce: If hospitalized Valeant chief makes an exit, it'll be without a golden parachute. More | Follow @CarlyHFierce

> Momenta Pharmaceuticals ($MNTA) announced deal to work with Mylan on 6 biosimilars. Release

> Mylan ($MYL) says CFO John Sheehan has said he will retire April 1. Release

> Court filings show that former Turing Pharmaceuticals CEO Martin Shkreli tapped a $45 million E*Trade account to make his bail after his arrest on securities charges. Story

> Janus Capital Corp. sold off about $1.5 billion worth of Allergan ($AGN) stock during the last quarter. Report

Medical Device News

@FierceMedDev: Bard to close Minnesota plant, eliminating 185 jobs. Article | Follow @FierceMedDev

@EmilyWFierce: $GSK halting speakers fees for docs in an effort to clean up its tarnished rep. More from the FT | Follow @EmilyWFierce

@VarunSaxena2: ICYMI: NEA partner outlines challenging med tech VC landscape heading into 2016. Article | Follow @VarunSaxena2

> Sony, Fujifilm reportedly considering bidding for Toshiba's $3B+ imaging device unit. More

> Validic app enables remote medical device data capture via smartphone camera. Report

> Michael J. Fox Foundation and Cynapsus team for wearable device study for Parkinson's. Article

Biotech News

@FierceBiotech: Zymeworks bags a $61.5M round, with a merger on tap and an IPO in view. Report | Follow @FierceBiotech

@JohnCFierce: Mylan bets $245M on a 50/50 biosimilar development pact with Momenta. Story | Follow @JohnCFierce

@DamianFierce: I feel like Bill Gross trying to get people to rise up against Bill Gross. More | Follow @DamianFierce

> Moderna's billion-dollar R&D shop partners up to finally enter the clinic. Report

> Sanofi and Regeneron line up for FDA approval with an arthritis treatment. Story

> Mylan bets $245M on a 50/50 biosimilar development pact with Momenta. Article

Suggested Articles

Merck is scouting replacements for CEO Ken Frazier with a preference toward an internal candidate, Bloomberg reports.

Bluebird Bio says the launch of Zynteglo, its first gene therapy, will not occur until 2020 while it tightens up its manufacturing processes.

Riival generics makers are squashing long-running lawsuits over their own versions of Sanofi's big-selling blood thinner Lovenox.